Cardio–Renal–Metabolic Syndrome: From Pathophysiological Mechanisms to Precision Medicine and Emerging Therapeutic Strategies:

A Comprehensive Narrative Review

By

Sarah Mohamed Alghamdi *

* Senior Medical Student , Ibn Sina National College for Medical Studies

Heba Safir Alhmada **

** Senior Medical Sstudent , Ibn Sina National College for Medical Studies

Afnan Ali Alhumayani ***

***Senior Medical Sstudent , Ibn Sina National College for Medical Studies

Dr./ Eman Mohamed ELNopy Mohamed****

******Bachelor of Pharmacy (Pharm D -Clinical)

Nawal Saad M Alshamrani *****

*******Critical Care Nursing , Nursing College ,Albaha University

Safa Ahmed Alouan ******

********Senior Medical Sstudent , Ibn Sina National College for Medical Studies

Ola Ahmed Alouan *******

*********Senior Medical Sstudent , Ibn Sina National College for Medical Studies

Maram Adel Anbari ********

********** 5th year medical student , Senior Medical Sstudent , Ibn Sina National College for Medical Studies

Abstract:

The concept of cardio-renal-metabolic (CKM) syndrome addresses a multisystem disorder linking cardiovascular diseases, chronic kidney disease, and metabolic disorders such as obesity and type 2 diabetes. These conditions are highly interconnected and influence one another through a complex network of chronic inflammation, oxidative stress, insulin resistance, and neurohormonal and vascular imbalances. This comprehensive narrative review explores the underlying pathophysiological mechanisms, identifying visceral obesity and adipose tissue dysfunction as critical starting points for a cascade of inflammatory reactions that damage blood vessels, kidneys, and the heart. It elucidates the crucial roles of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, and fibrosis in accelerating disease progression. Furthermore, the review discusses the clinical importance of early diagnosis, personalized risk stratification, and the application of precision medicine tailored to individual genetic, biological, and clinical profiles. From a therapeutic standpoint, we highlight the synergistic effectiveness of modern pharmacological strategies—including SGLT2 inhibitors, GLP-1 receptor agonists, non-steroidal mineralocorticoid receptor antagonists, and lipid-lowering therapies—alongside structured lifestyle interventions. Ultimately, an integrated, multidisciplinary healthcare approach is vital to significantly reduce cardiovascular and renal complications while improving long-term clinical outcomes.

Keywords: Cardio–Renal–Metabolic Syndrome - Pathophysiological Mechanisms - Precision Medicine - Emerging Therapeutic Strategies - Narrative Review.

Introduction:

Cardio-renal-metabolic (CKM) syndrome is an established clinical framework introduced by the American Heart Association (AHA) to describe the complex, bidirectional interrelationship between cardiovascular disease, chronic kidney disease (CKD), and metabolic disorders like obesity and type 2 diabetes. This framework marks a fundamental shift from treating individual organs in isolation to adopting a holistic, unified system approach. Overlapping inflammatory, metabolic, and neuroendocrine pathways create a reciprocal disease cycle where dysfunction in one system accelerates deterioration in the others, driving up global morbidity and mortality rates.

Visceral adiposity and insulin resistance serve as primary upstream triggers in this syndrome. Dysfunctional adipose tissue releases a cascade of pro-inflammatory cytokines and adipokines that promote chronic low-grade systemic inflammation, oxidative stress, and endothelial dysfunction. This microvascular injury activates the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS), ultimately accelerating vascular stiffness, hypertension, atherosclerosis, and progressive myocardial and renal fibrosis.

Concurrently, the clinical management of CKM syndrome is shifting toward precision medicine, where diagnostic and treatment pathways are tailored to individual genetic, biological, and clinical phenotypes. Modern technologies—including metabolomics, artificial intelligence (AI), and continuous data from wearable devices—have significantly enhanced early risk stratification and the subtyping of subclinical disease.

Compelling therapeutic innovations have transformed the management of CKM syndrome.

Novel agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and GLP-1 receptor agonists offer profound multi-organ protection, shielding the heart and kidneys while simultaneously optimizing metabolic metrics. Recent clinical evidence confirms that combining these targeted pharmacological treatments with integrated lifestyle interventions effectively mitigates the global disease burden, improves quality of life, and enhances long-term patient survival.

Study Objectives:

*To provide a comprehensive, literature-driven overview of Cardio–Renal–Metabolic (CKM) syndrome as an interconnected multisystem disorder.

* To explore the major shared pathophysiological mechanisms driving CKM progression, including chronic inflammation, oxidative stress, insulin resistance, endothelial damage, and neurohormonal overactivation.

* To evaluate the foundational role of visceral obesity, dysfunctional adipose tissue, and lipotoxicity in initiating the CKM cascade.

* To analyze the clinical utility of emerging biomarkers and advanced diagnostic technologies (e.g., metabolomics, AI, and wearable health devices) for early disease detection and phenotyping.

* To review recent advances in multi-organ protective therapies, focusing on SGLT2 inhibitors, GLP-1 receptor agonists, non-steroidal MRAs, and structured lifestyle modifications.

* To identify existing gaps in the current literature and propose future directions for integrated clinical practice and research.

Significance of the Study:

This comprehensive narrative review synthesizes the evolving scientific paradigm of CKM syndrome, reinforcing the need for multidisciplinary clinical care models over fragmented, single-organ interventions.

By clarifying the shared biological pathways linking cardiovascular, renal, and metabolic systems, this study provides clinicians, researchers, and healthcare professionals with an updated evidence base.

Highlighting the clinical efficacy of novel cardioprotective and nephroprotective drugs alongside cutting-edge digital health tools serves to guide optimized patient risk stratification. Ultimately, this review offers a valuable academic framework to assist policy makers in refining public health strategies, minimizing healthcare expenditures, and combating the expanding global burden of chronic cardiometabolic conditions.

Study Methodology:

This study utilizes a structured narrative review methodology to comprehensively synthesize and critically analyze the current body of literature regarding Cardio–Renal–Metabolic (CKM) syndrome. Given the broad and evolving nature of this multisystem continuum, a comprehensive literature search was conducted across major electronic databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar.

The search strategy employed combinations of relevant keywords and Medical Subject Headings (MeSH) terms, such as: "Cardio-Renal-Metabolic Syndrome", "Cardiovascular-Kidney-Metabolic Health", "Precision Medicine", "SGLT2 inhibitors", "GLP-1 receptor agonists", and "Pathophysiological Mechanisms".

To ensure the integration of up-to-date clinical evidence and recent therapeutic breakthroughs, the review prioritizes high-quality, peer-reviewed articles published in recent years, including key clinical trials, landmark scientific statements, and authoritative integrative reviews.

Literature published in English was assessed based on its relevance to CKM pathophysiology, staging, diagnostics, and integrated pharmacological and lifestyle management. The collected evidence was synthesized narratively to map out major thematic areas, identify consensus concepts, clarify clinical implications, and pinpoint critical remaining gaps in the research.

Research Problem and Study Justification:

The coexistence of cardiovascular disease, chronic kidney disease, obesity, hypertension, and type 2 diabetes mellitus represents one of the most severe public health challenges faced by modern healthcare systems. Despite significant independent diagnostic and therapeutic advancements within cardiology, nephrology, and endocrinology, global clinical outcomes remain suboptimal.

The primary challenge is the persistent reliance on fragmented, siloed clinical approaches where interconnected cardio-renal-metabolic conditions are managed as separate entities. This lack of integration leads to delayed diagnoses, incomplete risk

stratification, and a failure to implement early multi-organ protective therapies.

Furthermore, while a large portion of the global population exhibits subclinical stages of CKM syndrome, the real-world clinical implementation of precision medicine, advanced biomarkers, and AI-driven screening strategies remains poorly defined and inconsistent.

Consequently, conducting this comprehensive review is strongly justified to bridge these clinical silos. Synthesizing the latest evidence regarding shared biological pathways and multi-protective treatments provides an objective framework for establishing coordinated, multidisciplinary care models, improving long-term patient survival, and ensuring healthcare sustainability.

Conceptual Framework of CKM Syndrome:

Definition and Evolution of the CKM Concept:

Cardiovascular–kidney–metabolic (CKM) syndrome describes the deeply interconnected relationship between cardiovascular disease, chronic kidney disease, obesity, and diabetes mellitus. Formally defined by the American Heart Association, the concept unifies these conditions into a single clinical continuum driven by shared pathophysiological pathways. The evolution of the CKM framework represents a paradigm shift from separate cardiorenal or metabolic concepts toward a multisystem model that integrates obesity, kidney health, social determinants of health, and proactive lifestyle factors throughout a patient's life course.

Historical Overview of Cardio–Renal and Metabolic Interactions:

The bidirectional relationship between the heart and kidneys has long been recognized via the cardiorenal syndrome, where heart failure induces renal hypoperfusion, and CKD accelerates fluid overload and vascular calcification. Over recent decades, advanced molecular biology and epidemiological data revealed that metabolic conditions—primarily insulin resistance and visceral adiposity—act as the core drivers behind both cardiac and renal remodeling. The modern CKM framework reflects this deepened understanding of metabolic dysfunction as the common soil from which systemic vascular and organ diseases grow.

Classification and Stages of CKM Syndrome

To guide early screening and clinical interventions before irreversible organ damage occurs, CKM syndrome is classified into five progressive stages:

Stage 0: Represents individuals with optimal metabolic, renal, and cardiovascular health, showing no risk factors.

Stage 1: Characterized by excess or dysfunctional adiposity, such as abdominal obesity or prediabetes, without clear target-organ complications.

Stage 2: Defined by established metabolic risk factors, including clinical hypertension, type 2 diabetes mellitus, hypertriglyceridemia, or moderate chronic kidney disease.

Stage 3: Features subclinical cardiovascular disease, advanced CKD, or very high calculated cardiovascular risk, detected via imaging or sensitive biomarkers.

Stage 4: Represents clinically apparent cardiovascular disease, including heart failure, myocardial infarction, stroke, or end-stage kidney failure.

Epidemiology, Risk Factors, and Public Health Burden:

Driven by aging populations, urbanization, and sedentary habits, the global prevalence of CKM syndrome has reached critical proportions. Landmark systematic reviews estimate that metabolic syndrome alone affected over 1.5 billion adults, with global prevalence rates climbing significantly over the last two decades.

The disease burden is heavily magnified by obesity-related CKD and ischemic heart disease, with renal and cardiovascular disability-adjusted life years (DALYs) rising dramatically since 1990. Major risk factors encompass abdominal obesity, dyslipidemia, insulin resistance, smoking, chronic systemic inflammation, and deep-seated socioeconomic inequities.

Pathophysiological Mechanisms of CKM Syndrome:

1. Chronic Inflammation:

Chronic low-grade systemic inflammation (meta-inflammation) acts as a primary link bridging metabolic risk with organ damage. Visceral adipose tissue acts as an active endocrine organ that recruits immune cells and secretes pro-inflammatory cytokines, including TNF-\alpha, IL-1β, IL-6, and MCP-1. These circulating mediators trigger endothelial activation, impair insulin signaling pathways, and promote microvessel injury, directly driving the progression of obesity-related hypertension, diabetic nephropathy, and heart failure.

2. Oxidative Stress and Mitochondrial Dysfunction:

Oxidative stress develops when the production of reactive oxygen species (ROS) overwhelms endogenous antioxidant defenses. Hyperglycemia, insulin resistance, and mechanical shear stress markedly amplify cellular ROS generation. This excessive oxidative stress induces mitochondrial dysfunction, lipid peroxidation, and DNA damage within myocardial and renal tissues. Mitochondrial impairment decreases cellular ATP synthesis, causing vascular wall stiffening, podocyte injury, and accelerated myocardial hypertrophy.

3. Insulin Resistance and Metabolic Dysregulation:

In insulin-resistant states, impaired insulin signaling in peripheral tissues leads to chronic hyperglycemia and compensatory hyperinsulinemia. Hyperinsulinemia chronically overactivates the sympathetic nervous system and triggers renal sodium retention, causing hemodynamic stress. Furthermore, lipotoxicity from excessive circulating free fatty acids promotes dyslipidemia—marked by elevated triglycerides and small, dense LDL particles—which accelerates systemic atherosclerosis and glomerular injury.

4. Endothelial and Microvascular Dysfunction:

The vascular endothelium regulates tissue perfusion, vasodilation, and inflammatory cell adhesion via the balanced release of nitric oxide (NO). Under metabolic stress, endothelial

integrity is disrupted, causing a decline in NO bioavailability. This endothelial dysfunction impairs microvascular circulation, driving coronary microvascular ischemia (essential in heart failure with preserved ejection fraction) and disrupting the glomerular filtration barrier, which clinically manifests as progressive albuminuria.

5. Neurohormonal Activation (RAAS and SNS):

Chronic overactivation of the Renin-Angiotensin-Aldosterone System (RAAS) and the Sympathetic Nervous System (SNS) is a central feature of CKM syndrome. Elevated levels of Angiotensin II and aldosterone promote systemic vasoconstriction, persistent fluid retention, and oxidative signaling. Concurrently, sympathetic hyperactivity increases heart rate, myocardial oxygen demand, and renal renin release, creating a pathologic cardiorenal feedback loop that worsens left ventricular hypertrophy and accelerates chronic kidney disease.

6. Fibrosis and Organ Remodeling:

Fibrosis represents the final common pathway leading to permanent organ failure within the CKM continuum. Persistent inflammation, oxidative injury, and neurohormonal stress stimulate the transformation of resident fibroblasts into active myofibroblasts. Driven by profibrotic mediators like transforming growth factor-beta (TGF-\beta), these cells cause an excessive deposition of extracellular matrix proteins (collagen and fibronectin). This structural remodeling stiffens myocardial tissue—leading to arrhythmias and ventricular failure—and drives renal glomerulosclerosis and interstitial fibrosis.



Figure 1: Pathophysiological cascade and organ cross-talk driving Cardio-Renal-Metabolic (CKM) Syndrome progression.

Precision Medicine and Emerging Therapeutic Strategies:

The management of CKM syndrome has fundamentally evolved toward personalized risk assessment and holistic, multi-organ protective therapies. Rather than managing individual organ failures reactively, modern precision medicine integrates genomics, metabolomics, and machine learning algorithms to identify high-risk phenotypes and optimize individualized treatment strategies before irreversible target-organ injury occurs.

Pharmacological Innovations:

SGLT2 Inhibitors:

Foundations of CKM management, agents like empagliflozin and dapagliflozin offer potent cardioprotective and nephroprotective benefits far beyond glycemic control. They lower intraglomerular pressure, reduce systemic fluid overload, improve mitochondrial efficiency, and attenuate systemic inflammation.

GLP-1 Receptor Agonists:

Drugs such as semaglutide and tirzepatide are critical in addressing the metabolic roots of CKM syndrome. They significantly reduce visceral adiposity, improve insulin sensitivity, mitigate systemic inflammation, and lower the incidence of major adverse cardiovascular events (MACE).

Non-steroidal MRAs:

Finerenone selectively targets mineralocorticoid receptor overactivation, directly halting the inflammatory and profibrotic pathways that drive myocardial and renal remodeling.

Lifestyle and Digital Health Integration:

Comprehensive multidisciplinary care models combine these novel pharmacological therapies with first-line lifestyle cornerstones, including structured weight reduction, sleep optimization, and cardioprotective dietary patterns (e.g., Mediterranean or DASH diets). Furthermore, digital health innovations, such as wearable biosensors and continuous glucose monitoring (CGM) integrated with artificial intelligence, allow for real-time tracking of physiological biomarkers. This facilitates early clinical intervention and data-driven lifestyle modifications tailored to individual metabolic profiles.

Conclusion

Summary of Major Findings:

This comprehensive narrative review underscores that Cardio–Renal–Metabolic (CKM) syndrome is an interconnected multisystem disorder driven by shared, bidirectional biological pathways. Visceral adiposity, systemic meta-inflammation, oxidative stress, insulin resistance, neurohormonal overactivation, and progressive microvascular endothelial dysfunction form a complex pathological network that accelerates multi-organ damage. The review highlights that contemporary multi-organ protective interventions—particularly SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs—provide profound clinical benefits that interrupt this reciprocal disease cycle.

Clinical Implications and Recommendations:

Traditional, fragmented treatment models are no longer sufficient to manage CKM syndrome effectively. Clinical practice must transition toward integrated, multidisciplinary care teams involving cardiologists, nephrologists, endocrinologists, and primary care providers. Routine early screening using estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and cardiometabolic biomarkers is crucial for timely risk stratification.

Future research should prioritize large-scale, long-term longitudinal studies and clinical trials to evaluate emerging multi-incretin agonists and precision medicine-guided interventions. Furthermore, efforts must be directed toward exploring the integration of artificial intelligence and digital

therapeutics into routine clinical practice, ensuring health equity and global access to these life-saving therapeutic strategies.

Conflict of Interest Statement

The authors declare that they have no competing financial interests or personal relationships that could have influenced the work reported in this paper.

References:

Acierno, C., Orio, M., Schiavo, L., Saracino, A., & Stabile, E. (2026). From Metabolic Syndrome to Cardiovascular–Kidney–Metabolic Syndrome (CKM): A Clinical and Pathophysiological Continuum. Biomedicines, 14(4), 790.

Ahmad, M., Chevli, P., Mirzai, S., Spitz, J., Sharma, G., Lima, J., Nasir, K., Blaha, M., Pagidipati, N., Blumenthal, R., & Shapiro, M. (2025). Association between cardiovascular-kidney-metabolic syndrome, inflammatory biomarkers, and cardiovascular outcomes: Insights from the MESA study. Atherosclerosis, 410, 120521.

Ahmad, A., Lim, L., Morieri, M., Tam, C., Cheng, F., Chikowore, T., Dudenhöffer-Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., Sarkar, S., Koivula, R., Motala, A., Tye, S., Yu, G., Zhang, Y., Provenzano, M., Sherifali, D., de Souza, R., Tobias, D., Ma, R., & Mathioudakis, N. (2024). Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis. Communications Medicine (London), 4(1), 11.

American Heart Association. (2023). Heart disease risk, prevention and management redefined. AHA Scientific Statement.

Bansal, N., Weiner, D., & Sarnak, M. (2025). Cardiovascular-Kidney-Metabolic Health Syndrome: What Does the American Heart Association Framework Mean for Nephrology? Journal of the American Society of Nephrology, 35(5), 649–652.

Chen, Y., & Wu, G. (2025). Global, Regional, and National Burden of Chronic Kidney Disease Attributable to High Body Mass Index (BMI) among Individuals Aged 20-54 Years from 1990 to 2021. arXiv preprint, arXiv:2507.23537.

Chiuariu, T., Șalaru, D., Ureche, C., Vasiliu, L., Lupu, A., Lupu, V., Șerban, A., Zăvoi, A., Benchea, L., Clement, A., Tudurachi, B., Sascău, R., & Stătescu, C. (2024). Cardiac and Renal Fibrosis, the Silent Killer in the Cardiovascular Continuum: An Up-to-Date Review. Journal of Cardiovascular Development and Disease, 11(2), 62.

Chowdhury, D., Mishra, A., Kumari, N., Manna, R., Sahoo, A., Kumar, P., & Bodakhe, S. (2026). Exploring novel therapeutic approaches for managing cardiovascular-kidney-metabolic syndrome: A review of pharmacological advancements. Obesity Medicine, 61, 100704.

Claudel, S., & Verma, A. (2023). Cardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care. Cell Metabolism, 35(12), 2104-2106.

Ding, H., Jiang, L., Zhao, Y., Lee, D., & Chun, B. (2026). Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: a systematic review and meta-analysis. American Journal of Preventive Cardiology, 25, 101407.

Esmaeilpour, Z., Heydari, A., McDuff, D., Faranesh, A., Heneghan, C., Patel, S., Malhotra, M., Speed, C., Prieto, J., & Metwally, A. (2026). Cardiovascular-Kidney-Metabolic Health: Insights from Wearables and Blood Biomarkers. arXiv preprint, arXiv:2603.27787.

Fernando, K., Connolly, D., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, D. (2025). Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future. Diabetes Therapy, 16, 1155–1176.

Hassanabad, A., Zarzycki, A., & Fedak, P. (2024). Cellular and molecular mechanisms driving cardiac tissue fibrosis: On the precipice of personalized and precision medicine. Cardiovascular Pathology, 71, 107635.

Islam, S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024). The interplay of factors in metabolic syndrome: understanding its roots and complexity. Molecular Medicine, 30, 279.

Kittelson, K., Junior, A., Fillmore, N., & Gomes, R. (2024). Cardiovascular-kidney-metabolic syndrome – An integrative review. Progress in Cardiovascular Diseases, 87, 26-36.

Kuo, Y., Chen, L., Chen, Y., Chen, P., & Lin, H. (2025). Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies. International Journal of Molecular Sciences, 27(9), 4120.

Kushner, P., Khunti, K., Cebrián, A., & Deed, G. (2024). Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners. Advances in Therapy, 41, 3757–3770.

Lopez, D., Delgado, H., Villicaña, H., & Pérez, A. (2025). Cardio-Renal Syndrome: A Comprehensive Review of Pathophysiology, Clinical Subtypes, Diagnostic Challenges, and Therapeutic Strategies. International Journal of Medical Science and Clinical Research Studies, 05(07).

Mabhida, S., Mokoena, H., Sello, M., George, C., Ndlovu, M., Mabi, T., Martins, S., Ndlovu, I., Azu, O., Kengne, A., & Mchiza, Z. (2026). Inflammation as a Prognostic Marker in Cardiovascular Kidney Metabolic Syndrome: A Systematic Review. International Journal of Molecular Sciences, 27(1), 134.

Marassi, M., & Fadini, G. (2023). The cardio-renal-metabolic connection: a review of the evidence. Cardiovascular Diabetology, 22, 195.

Massy, Z., & Drueke, T. (2024). Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations. Kidney International Reports, 9(9), 2608-2618.

Maryam, M., Varghese, T., & Tazneem, B. (2024). Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Current Problems in Cardiology, 49(4), 102411.

Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J., Kordas, B., Rutkowska, J., & Juranek, J. (2025). Beyond the

Cardio–Renal–Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins. Journal of Clinical Medicine, 14(18), 6348.

Mavromatis, L., & Grams, M. (2026). Epidemiology of cardiovascular–kidney–metabolic syndrome. Nature Reviews Nephrology.

Metwally, A., Park, H., Wu, Y., McLaughlin, T., & Snyder, M. (2025). Use of Continuous Glucose Monitoring with Machine Learning to Identify Metabolic Subphenotypes and Inform Precision Lifestyle Changes. arXiv preprint, arXiv:2511.03986.

Minhas, A., Mathew, R., Sperling, L., Nambi, V., Salim, S., Virani, S., Navaneethan, D., Shapiro, M., & Abramov, D. (2024). Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. Journal of the American College of Cardiology, 83(18).

Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B., Șorodoc, L., Catar, O., & Lionte, C. (2025). Cardiovascular–Kidney–Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics? Journal of Clinical Medicine, 14(8), 2833.

Ndumele, C., Neeland, I., Tuttle, K., Chow, S., Mathew, R., Khan, S., Coresh, J., et al. (2026). A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation, 148(20).

Noubiap, J., Nansseu, J., Nyaga, U., Ndoadoumgue, A., Ngouo, A., Tounouga, D., Tianyi, F., Foka, A., Lontchi-Yimagou, E., Nkeck, J., & Bigna, J. (2025). Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nature Communications, 17(1), 573.

Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S., & Kirabo, A. (2025). Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome. Frontiers in Cardiovascular Medicine, 12.

Quaggin, S., & Magod, B. (2024). A united vision for cardiovascular-kidney-metabolic health. Nature Reviews Nephrology, 20(5), 273-274.

Robertson, S., Clarke, E., Gómez-Martín, M., Cross, V., Collins, C., & Stanford, J. (2024). Do Precision and Personalised Nutrition Interventions Improve Risk Factors in Adults with Prediabetes or Metabolic Syndrome? A Systematic Review of Randomised Controlled Trials. Nutrients, 16(10), 1479.

Rosen, S. (2026). Cardiovascular-Kidney-Metabolic Health Initiative. The American Heart Association's CKM Statistics.

Sebastian, S. A., Padda, I., & Johal, G. (2024). Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Current Problems in Cardiology, 49(2), 102344.

Singh, A., Kesani, H., Verma, S., Saleh, T., & Rai, M. (2025). Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management. Cureus, 17(10), e94134.

Triebel, H., & Castrop, H. (2024). The renin angiotensin aldosterone system. Pflügers Archiv - European Journal of Physiology, 476, 705–713.

Vora, J., Cherney, D., Kosiborod, M., Spaak, J., Kanumilli, N., Khunti, K., Lam, C., Bachmann, M., & Fenici, P. (2024). Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management. Diabetes, Obesity and Metabolism, 26(5), 1567-1581.

Wang, X., & He, B. (2024). Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm (2020), 5(8), e651.

Xu, Z., Yang, S., Tan, Y., Zhang, Q., Wang, H., Tao, J., Liu, Q., Wang, Q., Feng, W., Li, Z., Wang, C., & Cui, L. (2025). Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms–a comprehensive review. Molecular and Cellular Biochemistry, 480, 6039–6075.

Xie, Z., Yu, C., Cui, Q., Zhao, X., Zhuang, J., Chen, S., Guan, H., & Li, J. (2025). Global Burden of the Key Components of Cardiovascular-Kidney-Metabolic Syndrome. Journal of the American Society of Nephrology, 36(8), 1572-1584.

Zhang, B., & Schmidlin, T. (2024). Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology. npj Metabolic Health and Disease, article 25.